3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
6
Hematologic Neoplasms
5
Breast Neoplasms
4
Urinary Bladder Neoplasms
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Glioma
3
Colorectal Neoplasms
3
Prostatic Neoplasms
2
Neoplasms by Site
2
Motor Activity
2
Head and Neck Neoplasms
2
Glioblastoma
2
Carcinoma, Transitional Cell
2
Anxiety Disorders
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uveal Melanoma
1
Uterine Neoplasms
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Stomatitis
1
Stomach Neoplasms
1
Smoking Cessation
1
Small Cell Lung Carcinoma
1
Interventions
Gemcitabine
23
Cisplatin
16
pembrolizumab
6
Fluorouracil
6
pemigatinib
4
Radiotherapy
3
Oxaliplatin
3
Leucovorin
3
Drug Therapy
3
infigratinib
2
durvalumab
2
ceritinib
2
aldesleukin
2
Radiosurgery
2
Photochemotherapy
2
Nivolumab
2
Liver Transplantation
2
Dexamethasone
2
Cholangiopancreatography, Endoscopic Retrograde
2
Carboplatin
2
Capecitabine
2
trifluridine tipiracil drug combination
1
tremelimumab
1
trametinib
1
spartalizumab
1
seribantumab
1
perfluoro-2,2,2',2'-tetramethyl-4,4'-bis(1,3-dioxolane)
1
peginterferon alfa-2b
1
pazopanib
1
padeliporfin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Cholangiocarcinoma
×
Standard of Care
×
Clear all
NCT04099888
2023-09-11
RELEASE
PCI Biotech AS
Phase 2
Terminated
41 enrolled
17 charts